Welcome to our dedicated page for ProKidney SEC filings (Ticker: PROK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The ProKidney Corp. (PROK) SEC filings page brings together the company’s regulatory disclosures as a Nasdaq-listed biotechnology issuer developing autologous cellular therapies for chronic kidney disease (CKD). Through documents such as Form 8-K, Form 10-K, and Form 10-Q, ProKidney reports information about its financial condition, clinical development programs, capital markets activity, and material corporate events.
ProKidney’s recent Form 8-K filings illustrate how the company uses SEC reports to communicate key developments. These include press releases furnishing quarterly financial results, updates on cash, cash equivalents, and marketable securities, and commentary on research and development and general and administrative expenses. Other 8-Ks describe material definitive agreements, such as at-the-market equity offering arrangements under an Open Market Sale Agreement, and real estate transactions involving company property in Greensboro, North Carolina.
Filings also reference ProKidney’s clinical and regulatory progress for its lead product candidate, rilparencel (REACT®). For example, the company has furnished press releases via Form 8-K that discuss topline and full results from the Phase 2 REGEN-007 trial, the design and objectives of the Phase 3 REGEN-006 (PROACT 1) trial, and FDA alignment on using estimated glomerular filtration rate (eGFR) slope as a surrogate endpoint for an accelerated approval pathway. These documents provide context on how ProKidney presents its RMAT-designated program to regulators and investors.
Investors can also use SEC filings to track corporate structure and listing details, including ProKidney’s domestication from the Cayman Islands to the State of Delaware and confirmation that its Class A common stock trades on The Nasdaq Stock Market under the symbol PROK. On Stock Titan, AI-powered tools can help summarize lengthy filings, highlight key sections on clinical trial disclosures, financing arrangements, and risk factors, and make it easier to understand how new information in 8-K, 10-Q, and 10-K reports may relate to ProKidney’s CKD-focused development strategy.
ProKidney Corp. filed Post-Effective Amendment No. 3 to its S-1 on Form S-3, adopting the prior registration after its Delaware domestication under Rule 414. The prospectus now covers up to 169,635,462 shares of Class A common stock for resale by selling securityholders, reflecting updated holder information and a reduction in the number of shares offered since the initial registration.
The company states it will not receive any proceeds from sales by the selling securityholders and will bear registration-related expenses other than underwriting discounts and commissions. No additional securities are being registered in this amendment. ProKidney’s Class A common stock trades on Nasdaq under “PROK.”
ProKidney Corp. entered into a material definitive agreement to sell its Greensboro, North Carolina real property to Northpoint Development, LLC for approximately
The new agreement, signed on
ProKidney Corp. (Nasdaq: PROK) furnished a Current Report on Form 8-K stating that it issued a press release announcing its financial results for the quarter ended June 30, 2025. The press release is furnished as Exhibit 99.1, and the filing also references an Inline XBRL cover page file for the report.
The report notes that the furnished press release and related information are not being "filed" for purposes of certain Exchange Act liabilities and will not be incorporated by reference into other registration statements unless expressly stated. The filing identifies ProKidney as an emerging growth company and is signed on behalf of the registrant by Chief Financial Officer James Coulston.
ProKidney Corp. reported a substantial operating loss as it advances its lead autologous cell therapy, rilparencel, through late-stage trials while funding clinical and manufacturing operations. For the six months ended June 30, 2025 the consolidated net loss before noncontrolling interest was $74.9 million, cash and cash equivalents were $84.9 million and marketable securities totaled $209.8 million, giving combined short-term liquidity of about $294.7 million. Total assets were $372.1 million and stockholders' deficit was $1.0025 billion, reflecting a large redeemable noncontrolling interest of $1.342 billion.
The company is progressing Phase 3 PROACT 1 to support accelerated approval of rilparencel: the FDA agreed that eGFR slope can serve as a surrogate endpoint for an accelerated BLA and specified an acceptable effect size of at least 1.5 mL/min/1.73m2/year. ProKidney completed the REGEN-007 Phase 2 trial showing in one dosing arm a statistically significant improvement in annual eGFR slope of 4.6 mL/min/1.73m2/year (p<0.001). The company has enrolled nearly half the patients required for the accelerated approval analysis, with topline eGFR slope readout anticipated in Q2 2027.
Form 8-K filing highlights ProKidney Corp. (Nasdaq: PROK) furnished an 8-K dated 15 July 2025 to disclose two items under Regulation FD and Other Events.
Investor presentation (Item 7.01) Management placed an updated slide deck covering business, clinical studies, development plans and financial position on the company’s investor website and attached it as Exhibit 99.2. The company emphasizes that the material should be viewed in the context of prior SEC filings and does not undertake to update it unless required by law.
Press release on FDA alignment (Items 7.01 & 8.01) Exhibit 99.1 contains a same-day press release announcing “confirmation of alignment with the U.S. Food and Drug Administration on the accelerated approval pathway for rilparencel,” the company’s lead asset. The first two paragraphs of that release are incorporated by reference into Item 8.01, signifying potential material relevance.
No financial data The filing does not include earnings figures, balance-sheet information or guidance. It is being furnished rather than filed, so it is not subject to Section 18 liability.
Key takeaway for investors The disclosed FDA alignment represents a regulatory milestone that may reduce development risk for rilparencel. However, without accompanying clinical data, timelines or financial metrics, the magnitude of impact cannot be fully assessed from this filing alone.